Denali Capital Updates Share & Warrant Terms in 8-K Filing

TL;DR

**Denali Capital just confirmed its share and warrant terms, no big changes but good to know.**

AI Summary

Denali Capital Acquisition Corp. filed an 8-K on January 10, 2024, reporting an event on January 9, 2024. This filing indicates that the company, a SPAC, is providing updated information regarding its securities, specifically its Class A ordinary shares with a par value of $0.0001 per share and redeemable warrants exercisable at $11.50 per share. This matters to investors because it confirms the current structure of their investment and the terms under which warrants can be exercised, which is crucial for understanding potential dilution or future share price movements.

Why It Matters

This filing clarifies the terms of Denali Capital's shares and warrants, providing essential details for investors to understand their holdings and potential future value.

Risk Assessment

Risk Level: low — This filing is purely informational, updating the market on existing security terms without indicating new risks or significant operational changes.

Analyst Insight

An investor should review their current holdings of Denali Capital shares and warrants, understanding the exercise terms for warrants, but this filing itself doesn't warrant immediate action beyond acknowledging the updated information.

Key Numbers

• $0.0001 — Par Value per Share (This is the nominal value of each Class A ordinary share.)
• $11.50 — Warrant Exercise Price (This is the price at which each whole warrant can be exercised for one Class A ordinary share.)

Key Players & Entities

• Denali Capital Acquisition Corp. (company) — the registrant filing the 8-K
• $0.0001 (dollar_amount) — par value per Class A ordinary share
• $11.50 (dollar_amount) — exercise price per redeemable warrant
• January 9, 2024 (date) — date of earliest event reported
• January 10, 2024 (date) — date of filing

Forward-Looking Statements

• Denali Capital Acquisition Corp. will continue to operate as a SPAC, seeking a merger target. (Denali Capital Acquisition Corp.) — high confidence, target: 2024-12-31

FAQ

Key Financial Figures

• $0.0001 — LC Class A ordinary shares, par value $0.0001 per share DECA The Nasdaq Stock Mar
• $11.50 — ordinary share at an exercise price of $11.50 per share DECAW The Nasdaq Stock Ma
• $0.01 — one ordinary share of a par value of US$0.01 each (the "Consolidation"), such that f
• $22,100 — share capital of the Company shall be US$22,100 divided into 2,210,000 shares of a par

Filing Documents

• ea191397-8k_denalicap.htm (8-K) — 68KB
• 0001213900-24-002430.txt ( ) — 296KB
• deca-20240109.xsd (EX-101.SCH) — 4KB
• deca-20240109_def.xml (EX-101.DEF) — 27KB
• deca-20240109_lab.xml (EX-101.LAB) — 37KB
• deca-20240109_pre.xml (EX-101.PRE) — 25KB
• ea191397-8k_denalicap_htm.xml (XML) — 7KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On January 9, 2024, the shareholders of Denali Capital Acquisition Corp. (the "Company") held an extraordinary general meeting of shareholders (the "Shareholder Meeting") for the following purposes: (1) to consider and vote upon a proposal to approve by ordinary resolution (i) the Business Combination (as defined in the Merger Agreement), (ii) the adoption of the Agreement and Plan of Merger, dated as of January 25, 2023 (as amended by the Amendment to and Consent under Agreement and Plan of Merger dated April 11, 2023, the "Merger Agreement"), by and among the Company, Denali SPAC Holdco, Inc., a Delaware corporation and direct, wholly-owned subsidiary of the Company ("Holdco"), Denali SPAC Merger Sub, Inc., a Delaware corporation and direct, wholly-owned subsidiary of Holdco ("Denali Merger Sub"), Longevity Merger Sub, Inc., a Delaware corporation and direct, wholly-owned subsidiary of Holdco ("Longevity Merger Sub"), Longevity Biomedical, Inc., a Delaware corporation ("Longevity") and Bradford A. Zakes, solely in the capacity as a seller representative, (iii) the Plan of Merger in the form set forth in Annex B to the Proxy Statement (as defined herein) and (iv) the transactions contemplated by the Merger Agreement (the "Business Combination Proposal"); (2) to consider and vote upon a proposal to approve by special resolution the Denali Merger (as defined in the Proxy Statement) and related Plan of Merger and to authorize the merger of Denali Merger Sub with and into the Company, with the Company surviving the merger (the "Merger Proposal"); (3) to consider and vote upon a proposal to approve by ordinary resolution the alteration of the authorized share capital of the Company at the effective time of the Denali Merger by (a) the reclassification and re-designation of (i) 200,000,000 issued and unissued Class A ordinary shares of a par value of US$0.0001 each to 200,000,000 issued and unissued

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed with this Form 8-K: Exhibit No. Description of Exhibits 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 4 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DENALI CAPITAL ACQUISITION CORP. Dated: January 9, 2024 By: /s/ Lei Huang Name: Lei Huang Title: Chief Executive Officer 5

View Full Filing

View this 8-K filing on SEC EDGAR